WESTON, Fla., Sept. 14, 2004 (PRIMEZONE) -- TheSUBWAY.com announces the following stocks to its Stock Market Standouts List: Xechem International Inc. (OTCBB:XKEM), Juniper Networks Inc. (Nasdaq:JNPR), Sepracor Inc. (Nasdaq:SEPR), Applied Materials Inc. (Nasdaq:AMAT).
Xechem International, Inc. (OTC BB: XKEM) Xechem International, Inc., ("Xechem") just announced that it has received its eighth U.S. patent related to Paclitaxel (TAXOL(R)). This patent award extends the validity of the patents granted in China, Australia, New Zealand and seven European countries including Austria, Belgium, Ireland, France, Germany, Switzerland and the United Kingdom. Xechem now has over 20 international and domestic patents covering Paclitaxel and next it's generation taxane analogs.
Xechem International, Inc. is a fully integrated biopharmaceutical company focusing on phytopharmaceuticals and other proprietary technologies for orphan diseases. Its principal product under development is NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of sickle cell disease.
Other stocks highlighted include Juniper Networks Inc. (Nasdaq: JNPR): Stock Standouts List, Sepracor Inc. (Nasdaq: SEPR): Stock Standouts List, Applied Materials Inc. (NASDAQ: AMAT) Stock Standouts List.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed.
ABOUT TheSUBWAY.com:
TheSUBWAY.com, a leader in corporate communications and finance, provides all investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, etc., plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. For more daily commentary, go to http://www.thesubway.com/sub_comm.asp.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. (CRG has not been compensated but could receive up to one hundred thousand dollars for xkem. CRG has purchased approximately five hundred thousand shares of xkem in the open market.) CRG intends to sell its shares. CRG has sold approximately zero shares to date. CRG may sell its shares for less than the target price given in this opinion. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.